Raras
Buscar doenças, sintomas, genes...
Distrofia muscular congênita por distroglicanopatia
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Distrofias musculares congênitas são doenças musculares herdadas de forma autossômica recessiva. Elas são um grupo de distúrbios heterogêneos caracterizados por fraqueza muscular presente ao nascimento e pelas diferentes alterações na biópsia muscular, que variam de miopáticas a abertamente distróficas, devido à idade em que a biópsia é realizada.

Pesquisas ativas
2 ensaios
3 total registrados no ClinicalTrials.gov
Publicações científicas
23 artigos
Último publicado: 2024 Nov 26
🏥
SUS: Cobertura mínimaScore: 20%
Centros em: PA, PR, SC, RS, ES +10CID-10: G71.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
54 sintomas
💪
Músculos
52 sintomas
👁️
Olhos
33 sintomas
🦴
Ossos e articulações
23 sintomas
😀
Face
16 sintomas
❤️
Coração
12 sintomas

+ 127 sintomas em outras categorias

Características mais comuns

Morfologia anormal da substância branca cerebral
Fadiga fácil
Tronco cerebral dobrado
Fraqueza do tríceps
Dor torácica
Terceiro ventrículo dilatado
350sintomas
Sem dados (350)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 350 características clínicas mais associadas, ordenadas por frequência.

Morfologia anormal da substância branca cerebralAbnormal cerebral white matter morphology
Fadiga fácilEasy fatigability
Tronco cerebral dobradoKinked brainstem
Fraqueza do trícepsTriceps weakness
Dor torácicaChest pain

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Total histórico23PubMed
Últimos 10 anos135publicações
Pico201620 papers
Linha do tempo
20202015Hoje · 2026🧪 2005Primeiro ensaio clínico📈 2016Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

17 genes identificados com associação a esta condição.

POMKProtein O-mannose kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Protein O-mannose kinase that specifically mediates phosphorylation at the 6-position of an O-mannose of the trisaccharide (N-acetylgalactosamine (GalNAc)-beta-1,3-N-acetylglucosamine (GlcNAc)-beta-1,4-mannose) to generate phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-1,3-N-acetylglucosamine-beta-1,4-(phosphate-6-)mannose). Phosphorylated O-mannosyl trisaccharide is a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like d

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A12

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
6.4 TPM
Fibroblastos
5.9 TPM
Cérebro - Hemisfério cerebelar
3.0 TPM
Cerebelo
2.7 TPM
Testículo
2.3 TPM
OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12limb-girdle muscular dystrophy due to POMK deficiencyobsolete congenital muscular dystrophy with cerebellar involvementmuscular dystrophy-dystroglycanopathy, type A
HGNC:26267UniProt:Q9H5K3
POMT2Protein O-mannosyl-transferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
59.9 TPM
Pituitária
28.9 TPM
Tireoide
27.7 TPM
Cervix Endocervix
21.2 TPM
Cerebelo
21.2 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2autosomal recessive limb-girdle muscular dystrophy type 2Nmuscle-eye-brain disease
HGNC:19743UniProt:Q9UKY4
CRPPAD-ribitol-5-phosphate cytidylyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytidylyltransferase required for protein O-linked mannosylation (PubMed:22522420, PubMed:22522421, PubMed:26687144, PubMed:26923585, PubMed:27130732, PubMed:27601598). Catalyzes the formation of CDP-ribitol nucleotide sugar from D-ribitol 5-phosphate (PubMed:26687144, PubMed:26923585, PubMed:27130732). CDP-ribitol is a substrate of FKTN during the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carboh

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Umuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:37276UniProt:A4D126
B4GAT1Beta-1,4-glucuronyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,4-glucuronyltransferase involved in O-mannosylation of alpha-dystroglycan (DAG1) (PubMed:19587235, PubMed:23359570, PubMed:25279697, PubMed:25279699). Transfers a glucuronic acid (GlcA) residue onto a xylose (Xyl) acceptor to produce the glucuronyl-beta-1,4-xylose-beta disaccharide primer, which is further elongated by LARGE1, during synthesis of phosphorylated O-mannosyl glycan (PubMed:25279697, PubMed:25279699). Phosphorylated O-mannosyl glycan is a carbohydrate structure present in alp

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
Keratan sulfate biosynthesisMatriglycan biosynthesis on DAG1Defective LARGE causes MDDGA6 and MDDGB6
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A13

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (2)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A13muscular dystrophy-dystroglycanopathy, type A
HGNC:15685UniProt:O43505
RXYLT1Ribitol-5-phosphate xylosyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a UDP-D-xylose:ribitol-5-phosphate beta1,4-xylosyltransferase, which catalyzes the transfer of UDP-D-xylose to ribitol 5-phosphate (Rbo5P) to form the Xylbeta1-4Rbo5P linkage on O-mannosyl glycan (Probable) (PubMed:27733679, PubMed:29477842). Participates in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for bin

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A10

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (2)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10muscular dystrophy-dystroglycanopathy, type A
HGNC:13530UniProt:Q9Y2B1
GMPPBMannose-1-phosphate guanylyltransferase catalytic subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the GMPPA-GMPPB mannose-1-phosphate guanylyltransferase complex (PubMed:33986552). Catalyzes the formation of GDP-mannose, an essential precursor of glycan moieties of glycoproteins and glycolipids (PubMed:33986552). Can catalyze the reverse reaction in vitro (PubMed:33986552). Together with GMPPA regulates GDP-alpha-D-mannose levels (PubMed:33986552)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound intellectual disability. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
56.4 TPM
Tireoide
41.5 TPM
Linfócitos
39.6 TPM
Próstata
37.0 TPM
Glândula salivar
32.5 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14autosomal recessive limb-girdle muscular dystrophy type 2Tmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14muscle-eye-brain disease
HGNC:22932UniProt:Q9Y5P6
COL4A1Collagen alpha-1(IV) chainCandidate gene tested inAltamente restrito
FUNÇÃO

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. Specifically inhibits endothelial cell proliferation, migration and tube formation

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (1)
Collagen degradation
MECANISMO DE DOENÇA

Hereditary angiopathy with nephropathy aneurysms and muscle cramps

The clinical renal manifestations include hematuria and bilateral large cysts. Histologic analysis revealed complex basement membrane defects in kidney and skin. The systemic angiopathy appears to affect both small vessels and large arteries.

OUTRAS DOENÇAS (8)
brain small vessel disease 1 with or without ocular anomaliesautosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndromeretinal arterial tortuositymicroangiopathy and leukoencephalopathy, pontine, autosomal dominant
HGNC:2202UniProt:P02462
DPM2Dolichol phosphate-mannose biosynthesis regulatory proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Regulates the biosynthesis of dolichol phosphate-mannose (PubMed:10835346). Regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex; essential for the ER localization and stable expression of DPM1 (PubMed:10835346). Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:161628

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM1 causes DPM1-CDGSynthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1U

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1U patients have dystrophic changes seen on muscle biopsy and reduced O-mannosyl glycans on alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.9 TPM
Fibroblastos
64.0 TPM
Próstata
61.1 TPM
Cervix Endocervix
59.8 TPM
Cervix Ectocervix
57.1 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with intellectual disability and severe epilepsy
HGNC:3006UniProt:O94777
B3GALNT2UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc-beta-1-3GlcNAc, on N- and O-glycans. Has no galactose nor galactosaminyl transferase activity toward any acceptor substrate. Involved in alpha-dystroglycan (DAG1) glycosylation: acts coordinately with GTDC2/POMGnT2 to synthesize a GalNAc-beta3-GlcNAc-beta-terminus at the 4-position of protein O-mannose in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3

LOCALIZAÇÃO

Golgi apparatus membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A11

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11muscular dystrophy-dystroglycanopathy, type Aautosomal recessive non-syndromic intellectual disabilitymuscle-eye-brain disease
HGNC:28596UniProt:Q8NCR0
DPM3Dolichol-phosphate mannosyltransferase subunit 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex; tethers catalytic subunit DPM1 to the endoplasmic reticulum

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM1 causes DPM1-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15

An autosomal recessive, congenital muscular disorder characterized by hyperCKemia, myopathic features observed on muscle biopsy, developmental delay, mildly impaired intellectual development with learning difficulties, epilepsy, and mild white matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
101.0 TPM
Tireoide
86.4 TPM
Útero
85.8 TPM
Cervix Endocervix
81.3 TPM
Fallopian Tube
79.3 TPM
OUTRAS DOENÇAS (2)
DPM3-congenital disorder of glycosylationmuscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15
HGNC:3007UniProt:Q9P2X0
POMGNT2Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein. Involved in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular prote

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
98.5 TPM
Cerebelo
94.9 TPM
Cérebro - Hemisfério cerebelar
94.0 TPM
Ovário
60.0 TPM
Fallopian Tube
58.8 TPM
OUTRAS DOENÇAS (3)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8muscular dystrophy-dystroglycanopathy, type A
HGNC:25902UniProt:Q8NAT1
POMT1Protein O-mannosyl-transferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:12369018, PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
73.9 TPM
Cerebelo
65.0 TPM
Cérebro - Hemisfério cerebelar
61.3 TPM
Pituitária
32.9 TPM
Ovário
27.8 TPM
OUTRAS DOENÇAS (8)
autosomal recessive limb-girdle muscular dystrophy type 2Kmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1muscle-eye-brain disease
HGNC:9202UniProt:Q9Y6A1
FKRPRibitol 5-phosphate transferase FKRPDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842, PubMed:31949166). This constitutes the second step in the formation of the ribose 5-phosphate tandem repeat which links the phos

LOCALIZAÇÃO

Golgi apparatus membraneSecretedCell membrane, sarcolemmaRough endoplasmic reticulumCytoplasm

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A5

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
19.7 TPM
Útero
18.0 TPM
Fibroblastos
17.7 TPM
Tireoide
16.6 TPM
Fallopian Tube
16.5 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A5muscular dystrophy-dystroglycanopathy type B5autosomal recessive limb-girdle muscular dystrophy type 2Imuscle-eye-brain disease
HGNC:17997UniProt:Q9H9S5
DAG1Dystroglycan 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The dystroglycan complex is involved in a number of signaling events and processes including laminin deposition and extracellular matrix assembly, acetylcholine receptor clustering, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, epithelial polarization, and epithelium branching morphogenesis (By similarity). Required for the formation of photoreceptor ribbon synapses, and long-term maintenance of inhibitory synapses in cerebellar Purkinje cel

LOCALIZAÇÃO

Secreted, extracellular spaceSecreted, extracellular space, extracellular matrix, basement membraneSynapseCell membraneCytoplasm, cytoskeletonNucleus, nucleoplasmCell membrane, sarcolemmaPostsynaptic cell membrane

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy limb-girdle C9

An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
118.7 TPM
Artéria tibial
71.1 TPM
Aorta
69.5 TPM
Esôfago - Muscular
66.9 TPM
Esôfago - Junção
64.7 TPM
OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Pmuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9isolated asymptomatic elevation of creatine phosphokinasemuscular dystrophy-dystroglycanopathy, type A
HGNC:2666UniProt:Q14118
POMGNT1Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins (PubMed:11709191, PubMed:27493216, PubMed:28512129). Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties (PubMed:11709191, PubMed:27493216). Is specific for alpha linked terminal mannose and does not have MGAT3,

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
DAG1 core M1 glycosylationsDAG1 core M2 glycosylationsMatriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3

An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
61.9 TPM
Tireoide
61.2 TPM
Brain Spinal cord cervical c-1
57.1 TPM
Testículo
54.0 TPM
Nervo tibial
52.7 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3retinitis pigmentosa 76autosomal recessive limb-girdle muscular dystrophy type 2O
HGNC:19139UniProt:Q8WZA1
LARGE1Xylosyl- and glucuronyltransferase LARGE1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Bifunctional glycosyltransferase with both alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation of alpha-dystroglycan (DAG1) by glycosylation leading to DAG1 binding to laminin G-like domain-containing extracellular proteins with high affinity (PubMed:15661757, PubMed:15752776, PubMed:21987822, PubMed:22223806, PubMed:23125099, PubMed:25279697, PubMed:25279699). Elongates the glucuronyl-beta-1,4-xylose-beta disaccharide primer structure initiated

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B6

A congenital muscular dystrophy associated with profound intellectual disability, white matter changes and structural brain abnormalities. Skeletal muscle biopsies show reduced immunolabeling of alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon sigmoide
22.7 TPM
Útero
20.5 TPM
Coração - Ventrículo esquerdo
17.8 TPM
Fallopian Tube
16.4 TPM
Cervix Ectocervix
15.9 TPM
OUTRAS DOENÇAS (5)
muscular dystrophy-dystroglycanopathy type B6muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A6muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:6511UniProt:O95461
FKTNRibitol-5-phosphate transferase FKTNDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol-phosphate from CDP-ribitol to the distal N-acetylgalactosamine of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842). This constitutes the first step in the formation of the ribitol 5-phosphate tandem repeat which links the phosphorylated O-mannosyl trisaccharide to the ligan

LOCALIZAÇÃO

Golgi apparatus membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A4

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.9 TPM
Nervo tibial
12.9 TPM
Ovário
12.1 TPM
Útero
10.6 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4autosomal recessive limb-girdle muscular dystrophy type 2Mmuscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4dilated cardiomyopathy 1X
HGNC:3622UniProt:O75072

Variantes genéticas (ClinVar)

529 variantes patogênicas registradas no ClinVar.

🧬 POMK: NM_032237.5(POMK):c.43del (p.Arg15fs) ()
🧬 POMK: GRCh37/hg19 8p11.23-11.1(chr8:36650289-43776564)x3 ()
🧬 POMK: NM_032237.5(POMK):c.812A>G (p.Asp271Gly) ()
🧬 POMK: NM_032237.5(POMK):c.580C>A (p.His194Asn) ()
🧬 POMK: NM_032237.5(POMK):c.91_98dup (p.Leu34fs) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia muscular congênita por distroglicanopatia

Centros de Referência SUS

24 centros habilitados pelo SUS para Distrofia muscular congênita por distroglicanopatia

Centros para Distrofia muscular congênita por distroglicanopatia

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Infantil Albert Sabin

R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital Universitário da UFJF

R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442

Atenção Especializada

Rota
Anomalias Congênitas

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Julio Müller (HUJM)

R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092

Atenção Especializada

Rota
Anomalias Congênitas

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Lauro Wanderley (HULW)

R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470

Atenção Especializada

Rota
Anomalias Congênitas

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Pequeno Príncipe

R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805

Serviço de Referência

Rota
Anomalias CongênitasDeficiência Intelectual

Hospital Universitário Regional de Maringá (HUM)

Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Base de São José do Rio Preto

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798

Atenção Especializada

Rota
Anomalias Congênitas

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Epilepsy characteristics in patients with muscle-eye-brain disease: A systematic review of electroclinical features.

Epileptic disorders : international epilepsy journal with videotape2026 Mar 07

Muscle-Eye-Brain disease (MEB) is a dystroglycanopathy that belongs to the congenital muscular dystrophies. Central nervous system manifestations include congenital brain abnormalities, neurodevelopmental delay, and epilepsy, making it a rare but important cause of developmental and epileptic encephalopathy. This systematic review aims to explore all current literature data regarding clinical and electroencephalographic features of MEB cases with epilepsy. We conducted a literature review of previously published cases of patients with MEB and epilepsy in the PubMed and Scopus databases in the English language, focusing on seizure semiology and electroencephalographic features. We included 52 studies with 80 patients. The clinical spectrum of patients with MEB is broad, including hypotonia at birth, ocular symptoms, delay of motor milestones, and intellectual disability. Serum creatine kinase levels are significantly elevated (median value 1600 IU/L). POMGnT1 mutation is, by far, the most common mutation in MEB patients, reported in 38.8% of cases, followed by GMPPB (10%), FKTN, POMT2, or DPM2 mutations (less than 10%, respectively). Epilepsy is a common feature, with onset usually in the first 6 months of life. Absences are the most common seizure type (58.8% of patients), followed by generalized tonic-clonic (33.8%) and focal seizures (21.3%). Patients present with drug-resistant epilepsy in approximately one fourth of cases (21.3%). Electroencephalogram (EEG) shows focal or multifocal discharges in approximately half of the cases, with a predominance over frontal or temporal regions. Slow and disorganized EEG background activity is commonly observed in 92.9% of cases. Epilepsy is a common feature in MEB patients; its age of onset is usually in the first months of life, and it is often drug-resistant. It can manifest with all seizure types, with absences being the most common type. EEG shows focal or multifocal discharges with a slow and disorganized EEG background. The POMGnT1 mutation is the most common in MEB patients with epilepsy. A clear understanding of the electroclinical patterns in MEB patients can contribute to improved diagnostic precision and management.

#2

Clinical and Genetic Landscape of Children With Congenital Muscular Dystrophies From North India.

Journal of child neurology2025 Sep 22

Congenital muscular dystrophies are inherited disorders defined by early-onset muscle weakness, motor delay, and dystrophic muscle pathology. This study aimed to report the clinical and genetic landscape of children with congenital muscular dystrophies from North India. Cognitive and motor outcomes and quality of life were evaluated during follow-up. In a cross-sectional study, 42 children aged <18 years with clinical and genetic diagnosis of congenital muscular dystrophy were enrolled. The most common congenital muscular dystrophy subtype was COL6-related dystrophy (RD) (32%), followed by LAMA2-RD (26%), LMNA-RD (19%), α-dystroglycanopathy (α-DG; 9%), and CHKB-RD (5%). Motor and cognitive outcomes were was assessed in 33 (78%) children during follow-up, 45% (n = 19) were able to ambulate independently. Median value of the Motor Function Measure (MFM) score was 60 (interquartile range [IQR] 33-74), Brooke was 2 (IQR 1-4), and Vigno score was 6 (IQR 3-9). The median Medical Research Council sum score was 40 (IQR 29-47) and Vineland Social Maturity Scale (VSMS) score was 83.5 (IQR 64-86). The motor outcome and quality of life were worst affected in children with α-DG and LAMA2-RD. Hence, in a cohort of children with congenital muscular dystrophy from North India, COL6-RD and LAMA2-RD were the most common congenital muscular dystrophy subtypes. Motor impairment in children with congenital muscular dystrophy is profound, the majority being nonambulant and the children with α-DG most severely affected.

#3

Fukuyama congenital muscular dystrophy: Clinical features and therapeutic advances.

Brain &amp; development2025 Oct

Fukuyama congenital muscular dystrophy (FCMD, a severe form of muscular dystrophy characterized by brain structural anomalies and ocular complications due to neuronal migration disorders, is notably limited mainly to Japan. Ninety percent of patients are unable to walk throughout their lives and die before the age of 20 due to respiratory failure and cardiomyopathy. At present, there is no cure. The founder variant, a 3-kb insertion in FKTN, is an SVA (SINE-VNTR-Alu) retrotransposon, and FCMD is a splicing disorder attributable the exon trapping function of this retrotransposon. A splicing modulation therapy targeting exon-trapping based on using antisense nucleic acids to block abnormal splicing is under development, and clinical trials have begun. Additionally, it was clarified that the gene product of FKTN is a glycosyltransferase that transfers ribitol-5-phosphate from cytidine diphosphate ribitol, a precursor for the synthesis of the O-mannosyl glycans of α-dystroglycan, a cell membrane component. This finding raises hopes for a prodrug therapy. Though patient numbers were small, previous clinical studies suggested that steroids are effective in FCMD. Thus, phase II clinical trials are underway with the aim of obtaining insurance approval. This review provides an overview of the clinical course and current status of treatments being developed for FCMD.

#4

A child of congenital muscular dystrophy-dystroglycanopathy with a novel variant in the CRPPA gene: a case report and literature review.

Translational pediatrics2025 Jul 31

Dystroglycanopathy is a genetically heterogeneous group of rare muscular dystrophies that affect the brain, muscles, and eyes, primarily resulting from impaired glycosylation of α-dystroglycan. In this study, we identify and characterize a novel heterozygous CRPPA gene variant causally associated with α-dystroglycanopathy. We present a case of a 1-year and 5-month-old female with elevated creatine kinase (CK) levels and seizures, along with global developmental delay, microphthalmia, hypotonia, and myasthenia. Notably absent was ocular involvement. The serum CK levels typically fluctuated between 2,356 and 9,555 U/L. Video-electroencephalogram monitoring demonstrated abnormal discharge in the left anterior frontal region. Brain magnetic resonance imaging revealed numerous subcortical cysts in the bilateral cerebellar hemispheres and corpus callosum dysplasia. We performed whole-exome sequencing to identify compound heterozygous mutations in the CRPPA gene [Online Mendelian Inheritance in Man (OMIM): 614643]. The identified mutations include the pathogenic variant c.1251G>A (p. Gln 417=) inherited from father, and the c.1119+2T>G variant inherited from mother. We confirm that c.1119+2T>G was a novel splice-site variant. Based on the clinical manifestations, ancillary tests, and genetic results, the patient was diagnosed with congenital muscular dystrophy with mental retardation (CMD-MR). Levetiracetam effectively controlled the seizures. However, the patient's motor and cognitive impairments remained unaddressed by pharmacological interventions and persisted backward. We present a case of α-dystroglycanopathy caused by a novel splice site variant, c.1119+2T>G, in the CRPPA gene. The patient presented with clinical features characteristic of CMD-MR, thus extending the phenotypic spectrum of α-dystroglycanopathy.

#5

Variable Ophthalmologic Phenotypes Associated with Biallelic Loss-of-Function Variants in POMGNT1.

International journal of molecular sciences2025 Apr 01

O-mannosylation is a post-translational modification required for the proper function of various proteins and critical for development and growth. POMGNT1 encodes the enzyme O-linked-mannose β-1,2-N-acetylglucosaminyltransferase 1, which catalyzes the second step in the synthesis of α-dystroglycan O-mannosyl glycans. Among POMGNT1-related α-dystroglycanopathies, muscle-eye-brain (MEB) disease presents with congenital muscular dystrophy, structural brain abnormalities, and retinal dystrophy. Defects in protein O-mannosylation due to biallelic loss-of-function POMGNT1 mutations produce disturbances in assembling and organizing the basal membrane in the neuroretinal system, involving both the central and peripheral nervous systems. In the retina, POMGNT1 is expressed in photoreceptors and is localized near the photoreceptor cilium basal body, a structure critical for protein transport. Recent studies have reported an isolated degenerative ocular phenotype without any involvement of muscular or neuronal tissues. Here, we report on a family with three siblings affected by an apparently isolated clinically variable retinal disease and sharing biallelic inactivating POMGNT1 variants. Notably, the rod-cone dystrophy phenotype in the three siblings varied significantly in onset, presentation, and severity. These findings provide further evidence of the clinical variability associated with defective POMGNT1 function.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 135

2026

Epilepsy characteristics in patients with muscle-eye-brain disease: A systematic review of electroclinical features.

Epileptic disorders : international epilepsy journal with videotape
2025

Expression of Dystroglycanopathy-Related Enzymes, POMGNT2 and POMGNT1, in the Mammalian Retina and 661W Cone-like Cell Line.

Biomedicines
2025

Ophthalmologic manifestations associated with Fukutin (FKTN) variant subtypes in Korean patients with Fukuyama congenital muscular dystrophy: a single-center retrospective case series.

BMC ophthalmology
2025

Clinical and Genetic Landscape of Children With Congenital Muscular Dystrophies From North India.

Journal of child neurology
2025

Fukuyama congenital muscular dystrophy: Clinical features and therapeutic advances.

Brain &amp; development
2025

A child of congenital muscular dystrophy-dystroglycanopathy with a novel variant in the CRPPA gene: a case report and literature review.

Translational pediatrics
2025

Variable Ophthalmologic Phenotypes Associated with Biallelic Loss-of-Function Variants in POMGNT1.

International journal of molecular sciences
2025

Child Neurology: Severe GMPPB-Related Congenital Muscular Dystrophy With Rapidly Progressive Encephalopathy Leading to Infantile Death.

Neurology
2024

Metabolic Engineering of Glycofusion Bispecific Antibodies for α-Dystroglycanopathies.

Antibodies (Basel, Switzerland)
2024

Walker-Warburg syndrome: A case report of congenital muscular dystrophy with hydrocephalus.

Radiology case reports
2024

Phenotype-genotype spectrum of a cohort of congenital muscular dystrophies: a single-centre experience from India.

Neurogenetics
2023

Mild limb girdle muscular dystrophy R9 phenotype caused by novel compound heterozygous FKRP gene mutation.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2024

Genetic blueprint of congenital muscular dystrophies with brain malformations in Egypt: A report of 11 families.

Neurogenetics
2024

Removal of pomt1 in zebrafish leads to loss of α-dystroglycan glycosylation and dystroglycanopathy phenotypes.

Human molecular genetics
2024

Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy.

eLife
2024

Endogenous reductase activities for the generation of ribitol-phosphate, a CDP-ribitol precursor, in mammals.

Journal of biochemistry
2023

Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.

Molecular therapy : the journal of the American Society of Gene Therapy
2023

Uniparental disomy for chromosome 1 with POMGNT1 splice-site variant causes muscle-eye-brain disease.

Frontiers in genetics
2023

Progress in muscle research through the international congress of neuromuscular diseases (ICNMD): a narrative review.

European journal of translational myology
2023

Broad spectrum of phenotype and genotype in Korean α-dystroglycan related muscular dystrophy presenting to a tertiary pediatric neuromuscular center.

Neuromuscular disorders : NMD
2023

Three siblings with variable degrees of neuromuscular involvement and congenital sideroblastic anemia: A peculiar phenotype and a surprise genotypic explanation.

Annals of human genetics
2023

GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders.

Genes
2023

Electroretinogram abnormalities in FKRP-related limb-girdle muscular dystrophy (LGMDR9).

Documenta ophthalmologica. Advances in ophthalmology
2023

The many roles of dystroglycan in nervous system development and function: Dystroglycan and neural circuit development: Dystroglycan and neural circuit development.

Developmental dynamics : an official publication of the American Association of Anatomists
2022

Genetics and muscle pathology in the diagnosis of muscular dystrophies: An update.

Indian journal of pathology &amp; microbiology
2022

Congenital muscle dystrophies: Role of singleton whole exome sequencing in countries with limited resources.

Clinical neurology and neurosurgery
2022

Expanding the Phenotype of B3GALNT2-Related Disorders.

Genes
2022

Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.

European journal of translational myology
2021

Dystroglycanopathy: From Elucidation of Molecular and Pathological Mechanisms to Development of Treatment Methods.

International journal of molecular sciences
2021

Intellectual disability in paediatric patients with genetic muscle diseases.

Neuromuscular disorders : NMD
2021

Muscular dystrophy-dystroglycanopathy in a family of Labrador retrievers with a LARGE1 mutation.

Neuromuscular disorders : NMD
2021

Defective autophagy and increased apoptosis contribute toward the pathogenesis of FKRP-associated muscular dystrophies.

Stem cell reports
2022

Distinct and Recognisable Muscle MRI Pattern in a Series of Adults Harbouring an Identical GMPPB Gene Mutation.

Journal of neuromuscular diseases
2022

B4GAT1 Gene Associated Congenital Muscular Dystrophy Presenting with Recurrent Severe Ventriculomegaly: Case Report and Review of Literature.

Fetal and pediatric pathology
2021

POMT1 and POMT2 gene mutations result in 2 cases of alpha-dystroglycanopathy.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
2021

FKRP mutations cause congenital muscular dystrophy 1C and limb-girdle muscular dystrophy 2I in Asian patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2021

Phenotype and Genotype Study of Chinese POMT2-Related α-Dystroglycanopathy.

Frontiers in genetics
2021

Homozygous deletion, c. 1114-1116del, in exon 8 of the CRPPA gene causes congenital muscular dystrophy in Chinese family: A case report.

World journal of clinical cases
2021

New phenotype caused by POMGNT2 mutations.

BMJ case reports
2021

Revertant Phenomenon in DMD and LGMD2I and Its Therapeutic Implications: A Review of Study Under Mentorship of Terrence Partridge.

Journal of neuromuscular diseases
2021

Retinal Proteomics of a Mouse Model of Dystroglycanopathies Reveals Molecular Alterations in Photoreceptors.

Journal of proteome research
2021

A homozygous mutation in the POMT2 gene in four siblings with limb-girdle muscular dystrophy 2N.

Turkish archives of pediatrics
2021

The structure of POMGNT2 provides new insights into the mechanism to determine the functional O-mannosylation site on α-dystroglycan.

Genes to cells : devoted to molecular &amp; cellular mechanisms
2021

Crystal structures of β-1,4-N-acetylglucosaminyltransferase 2: structural basis for inherited muscular dystrophies.

Acta crystallographica. Section D, Structural biology
2020

A Child of Congenital Muscular Dystrophy-Dystroglycanopathy with Homozygous Missense Variation in Exon 3 of the ISPD Gene: A Rare Case from Odisha.

Advanced biomedical research
2021

Compound heterozygous variants in GOSR2 associated with congenital muscular dystrophy: A case report.

European journal of medical genetics
2021

Glycosyltransferase POMGNT1 deficiency strengthens N-cadherin-mediated cell-cell adhesion.

The Journal of biological chemistry
2021

NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.

eLife
2021

Fukutin-Related Protein: From Pathology to Treatments.

Trends in cell biology
2021

Genetic variations and clinical spectrum of dystroglycanopathy in a large cohort of Chinese patients.

Clinical genetics
2021

Characteristic Cochlear Hypoplasia in Patients with Walker-Warburg Syndrome: A Radiologic Study of the Inner Ear in α-Dystroglycan-Related Muscular Disorders.

AJNR. American journal of neuroradiology
2020

Phenotypic Spectrum of α-Dystroglycanopathies Associated With the c.919T>a Variant in the FKRP Gene in Humans and Mice.

Journal of neuropathology and experimental neurology
2020

Further evidence for POMK as candidate gene for WWS with meningoencephalocele.

Orphanet journal of rare diseases
2020

The first report of two homozygous sequence variants in FKRP and SELENON genes associated with syndromic congenital muscular dystrophy in Iran: Further expansion of the clinical phenotypes.

The journal of gene medicine
2020

Early and long-term effect of the treatment with pyridostigmine in patients with GMPPB-related congenital myasthenic syndrome.

Neuromuscular disorders : NMD
2020

Brain Dysfunction in LAMA2-Related Congenital Muscular Dystrophy: Lessons From Human Case Reports and Mouse Models.

Frontiers in molecular neuroscience
2020

The Common miRNA Signatures Associated with Mitochondrial Dysfunction in Different Muscular Dystrophies.

The American journal of pathology
2020

Reporting one very rare pathogenic variation c.1106G>A in POMT2 gene.

Intractable &amp; rare diseases research
2020

Congenital hearing impairment associated with peripheral cochlear nerve dysmyelination in glycosylation-deficient muscular dystrophy.

PLoS genetics
2020

FAM3B/PANDER-Like Carbohydrate-Binding Domain in a Glycosyltransferase, POMGNT1.

Methods in molecular biology (Clifton, N.J.)
2020

Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy.

Nature communications
2020

biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies.

Molecular therapy : the journal of the American Society of Gene Therapy
2020

Pathogenic homozygous variant in POMK gene is the cause of prenatally detected severe ventriculomegaly in two Lithuanian families.

American journal of medical genetics. Part A
2020

Muscular, Ocular and Brain Involvement Associated with a De Novo 11q13.2q14.1 Duplication: Contribution to the Differential Diagnosis of Muscle-Eye-Brain Congenital Muscular Dystrophy.

Journal of neuromuscular diseases
2019

A mutation in mannose-phosphate-dolichol utilization defect 1 reveals clinical symptoms of congenital disorders of glycosylation type I and dystroglycanopathy.

JIMD reports
2020

Just Expect It: Compound Heterozygous Variants of POMT1 in a Consanguineous Family-The Role of Next Generation Sequencing in Neuromuscular Disorders.

Neuropediatrics
2019

Two middle-aged women with the Finnish variant of muscle-eye-brain disease (MEB).

American journal of medical genetics. Part A
2019

A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan.

EMBO reports
2019

Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene.

Neuromuscular disorders : NMD
2019

Advances in imaging of brain abnormalities in neuromuscular disease.

Therapeutic advances in neurological disorders
2019

Congenital muscular dystrophies in China.

Clinical genetics
2019

Compound heterozygous POMGNT1 mutations leading to muscular dystrophy-dystroglycanopathy type A3: a case report.

BMC pediatrics
2018

Congenital Muscular Dystrophy due to Novel Compound Heterozygote Mutations in POMGNT1 Gene.

Journal of pediatric neurosciences
2019

Toward understanding tissue-specific symptoms in dolichol-phosphate-mannose synthesis disorders; insight from DPM3-CDG.

Journal of inherited metabolic disease
2018

LARGE expression in different types of muscular dystrophies other than dystroglycanopathy.

BMC neurology
2018

Molecular genetics of the POMT1-related muscular dystrophy-dystroglycanopathies.

Mutation research. Reviews in mutation research
2018

Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study.

Orphanet journal of rare diseases
2018

Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.

Nature communications
2018

Steroid therapy in an alpha-dystroglycanopathy due to GMPPB gene mutations: A case report.

Neuromuscular disorders : NMD
2018

A new case expanding the mutation and phenotype spectrum of TMEM5-related alpha-dystroglycanopathy.

Neuromuscular disorders : NMD
2018

Bilateral cerebellar cysts and cerebral white matter lesions with cortical dysgenesis: Expanding the phenotype of LAMB1 gene mutations.

Clinical genetics
2018

CDP-glycerol inhibits the synthesis of the functional O-mannosyl glycan of α-dystroglycan.

The Journal of biological chemistry
2018

Overexpression of Mutant FKRP Restores Functional Glycosylation and Improves Dystrophic Phenotype in FKRP Mutant Mice.

Molecular therapy. Nucleic acids
2018

TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy.

Skeletal muscle
2018

B3GALNT2-Related Dystroglycanopathy: Expansion of the Phenotype with Novel Mutation Associated with Muscle-Eye-Brain Disease, Walker-Warburg Syndrome, Epileptic Encephalopathy-West Syndrome, and Sensorineural Hearing Loss.

Neuropediatrics
2018

Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy.

Skeletal muscle
2018

Congenital muscular dystrophy-dystroglycanopathy, type A, featuring bilateral retinal dysplasia and vertical angle kappa.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2018

Mobility shift of beta-dystroglycan as a marker of GMPPB gene-related muscular dystrophy.

Journal of neurology, neurosurgery, and psychiatry
2018

Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage.

Human molecular genetics
2017

B3GALNT2 mutations associated with non-syndromic autosomal recessive intellectual disability reveal a lack of genotype-phenotype associations in the muscular dystrophy-dystroglycanopathies.

Genome medicine
2018

A Homozygous LAMA2 Mutation of c.818G>A Caused Partial Merosin Deficiency in a Japanese Patient.

Internal medicine (Tokyo, Japan)
2017

Cystic kidneys in fetal Walker-Warburg syndrome with POMT2 mutation: Intrafamilial phenotypic variability in four siblings and review of literature.

American journal of medical genetics. Part A
2017

Dystroglycan Maintains Inner Limiting Membrane Integrity to Coordinate Retinal Development.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2017

Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan.

Biochimica et biophysica acta. General subjects
2017

Congenital muscular dystrophies in the UK population: Clinical and molecular spectrum of a large cohort diagnosed over a 12-year period.

Neuromuscular disorders : NMD
2017

Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.

Human molecular genetics
2017

Mammalian O-mannosylation of cadherins and plexins is independent of protein O-mannosyltransferases 1 and 2.

The Journal of biological chemistry
2017

Efficacy of Gene Therapy Is Dependent on Disease Progression in Dystrophic Mice with Mutations in the FKRP Gene.

Molecular therapy. Methods &amp; clinical development
2017

Serial prenatal and postnatal MRI of dystroglycanopathy in a patient with familial B3GALNT2 mutation.

Pediatric radiology
2017

3D structural analysis of protein O-mannosyl kinase, POMK, a causative gene product of dystroglycanopathy.

Genes to cells : devoted to molecular &amp; cellular mechanisms
2017

Mutations in INPP5K Cause a Form of Congenital Muscular Dystrophy Overlapping Marinesco-Sjögren Syndrome and Dystroglycanopathy.

American journal of human genetics
2017

Compound heterozygous POMT1 mutations in a Chinese family with autosomal recessive muscular dystrophy-dystroglycanopathy C1.

Journal of cellular and molecular medicine
2016

A Successful Treatment of Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization for Hydrocephalus in Walker-Warburg Syndrome.

Case reports in neurological medicine
2017

Congenital mirror movements in a patient with alpha-dystroglycanopathy due to a novel POMK mutation.

Neuromuscular disorders : NMD
2017

Evidence of early defects in Cajal-Retzius cell localization during brain development in a mouse model of dystroglycanopathy.

Neuropathology and applied neurobiology
2017

Two patients with GMPPB mutation: The overlapping phenotypes of limb-girdle myasthenic syndrome and limb-girdle muscular dystrophy dystroglycanopathy.

Muscle &amp; nerve
2016

Direct Mapping of Additional Modifications on Phosphorylated O-glycans of α-Dystroglycan by Mass Spectrometry Analysis in Conjunction with Knocking Out of Causative Genes for Dystroglycanopathy.

Molecular &amp; cellular proteomics : MCP
2016

Biallelic Mutations in TMTC3, Encoding a Transmembrane and TPR-Containing Protein, Lead to Cobblestone Lissencephaly.

American journal of human genetics
2016

The Muscular Dystrophy Gene TMEM5 Encodes a Ribitol β1,4-Xylosyltransferase Required for the Functional Glycosylation of Dystroglycan.

The Journal of biological chemistry
2016

Neuronal Dystroglycan Is Necessary for Formation and Maintenance of Functional CCK-Positive Basket Cell Terminals on Pyramidal Cells.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2016

Congenital muscular dystrophy: from muscle to brain.

Italian journal of pediatrics
2016

Gallus gallus orthologous to human alpha-dystroglycanopathies candidate genes: Gene expression and characterization during chicken embryogenesis.

Biochemical and biophysical research communications
2016

Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.

Proceedings of the National Academy of Sciences of the United States of America
2016

Tmem2 regulates cell-matrix interactions that are essential for muscle fiber attachment.

Development (Cambridge, England)
2016

FKRP mutations, including a founder mutation, cause phenotype variability in Chinese patients with dystroglycanopathies.

Journal of human genetics
2015

Ultrasound diagnosis of bilateral cataracts in a fetus with possible cerebro-ocular congential muscular dystrophy during the routine second trimester anomaly scan.

Ultrasound (Leeds, England)
2016

Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review.

Molecular aspects of medicine
2016

Homozygosity Mapping and Whole-Genome Sequencing Links a Missense Mutation in POMGNT1 to Autosomal Recessive Retinitis Pigmentosa.

Investigative ophthalmology &amp; visual science
2016

Functional Similarities between the Protein O-Mannosyltransferases Pmt4 from Bakers' Yeast and Human POMT1.

The Journal of biological chemistry
2016

TMEM5-associated dystroglycanopathy presenting with CMD and mild limb-girdle muscle involvement.

Neuromuscular disorders : NMD
2016

Analysis of phenotype, enzyme activity and genotype of Chinese patients with POMT1 mutation.

Journal of human genetics
2016

Clinical features of the myasthenic syndrome arising from mutations in GMPPB.

Journal of neurology, neurosurgery, and psychiatry
2016

Global serum glycoform profiling for the investigation of dystroglycanopathies & Congenital Disorders of Glycosylation.

Molecular genetics and metabolism reports
2016

Prenatal muscle development in a mouse model for the secondary dystroglycanopathies.

Skeletal muscle
2015

[Application of targeted capture technology and next generation sequencing in molecular diagnosis of inherited myopathy].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2015

GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation.

Human mutation
2016

Degree of Cajal-Retzius Cell Mislocalization Correlates with the Severity of Structural Brain Defects in Mouse Models of Dystroglycanopathy.

Brain pathology (Zurich, Switzerland)
2015

Nonmechanical Roles of Dystrophin and Associated Proteins in Exercise, Neuromuscular Junctions, and Brains.

Brain sciences
2015

Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.

Brain : a journal of neurology
2015

Ectopic clustering of Cajal-Retzius and subplate cells is an initial pathological feature in Pomgnt2-knockout mice, a model of dystroglycanopathy.

Scientific reports
2016

Differential diagnosis of ventriculomegaly and brainstem kinking on fetal MRI.

Brain &amp; development
2015

Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane.

Glycobiology
2015

Expanding the phenotype of GMPPB mutations.

Brain : a journal of neurology
2015

Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.

Scientific reports
2015

Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein.

Journal of neuromuscular diseases

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia muscular congênita por distroglicanopatia.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia muscular congênita por distroglicanopatia

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Epilepsy characteristics in patients with muscle-eye-brain disease: A systematic review of electroclinical features.
    Epileptic disorders : international epilepsy journal with videotape· 2026· PMID 41793234mais citado
  2. Clinical and Genetic Landscape of Children With Congenital Muscular Dystrophies From North India.
    Journal of child neurology· 2025· PMID 40982308mais citado
  3. Fukuyama congenital muscular dystrophy: Clinical features and therapeutic advances.
    Brain &amp; development· 2025· PMID 40914050mais citado
  4. A child of congenital muscular dystrophy-dystroglycanopathy with a novel variant in the CRPPA gene: a case report and literature review.
    Translational pediatrics· 2025· PMID 40800181mais citado
  5. Variable Ophthalmologic Phenotypes Associated with Biallelic Loss-of-Function Variants in POMGNT1.
    International journal of molecular sciences· 2025· PMID 40244109mais citado
  6. Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy.
    Neurology· 2024· PMID 39475687recente
  7. Congenital Muscular Dystrophy Due to Merosin Deficiency: Report of a New Mutation.
    Cureus· 2023· PMID 37416022recente
  8. Megaconial congenital muscular dystrophy due to CHKB gene variants, the first report of thirteen Iranian patients.
    Neuromuscul Disord· 2023· PMID 37393748recente
  9. Large heterozygous deletion and uniparental disomy masquerading as homozygosity in CHKB gene.
    Mol Genet Genomic Med· 2023· PMID 36896673recente
  10. Megaconial congenital muscular dystrophy due to novel CHKB variants: a case report and literature review.
    Skelet Muscle· 2022· PMID 36175989recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:370953(Orphanet)
  2. MONDO:0018276(MONDO)
  3. GARD:12584(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q18553324(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distrofia muscular congênita por distroglicanopatia
Compêndio · Raras BR

Distrofia muscular congênita por distroglicanopatia

ORPHA:370953 · MONDO:0018276
CID-10
G71.2 · Miopatias congênitas
Ensaios
2 ativos
MedGen
UMLS
C5679911
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades